89zr-amg211
mAbexperimentalMulti-specificImaging agent
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT02760199)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Carcinoembryonic antigen-related cell adhesion molecule 5Immunity, passive
CEACAM5 immunity, passive
- Lymphocyte differentiation antigen CD38Radiopharmaceutical
CD38 radiopharmaceutical
Chemistry & pharmacology
- Multi-specific
- Yes
- Imaging
- 89-Zirconium
Oral
No
Parenteral
No
Topical
No
Also known as
- 89zr amg 211
- 89zr-amg211
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02760199 | Phase 1 | Aug 1, 2016 | University of Groningen |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Groningen | Academic/Hospital | 1 | 1 | 1 | 2016 |
1 organizations
Page 1 / 1